Arbutus Biopharma Corporation · Nasdaq
Biotechnology / Infectious Disease & IP Monetization
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease, LNP patent monetization, and shareholder capital return.
Price
$5.01
Session change
-1.18%
Day range
$4.98–$5.05
Volume
6.5M
20-day avg volume
5.6M
catalyst · Arbutus Biopharma — Q2 2026 Corporate Update / Form 10-Q
Arbutus previously disclosed receipt of $178.4 million as its share of the noncontingent Moderna settlement payment and said it expects to return up to approximately $230 million to shareholders through share repurchases. The form remains subject to board approval and execution uncertainty.
Sourcecatalyst · Arbutus Investor Relations / SEC Form 8-K
Arbutus confirmed receipt of ~$178.4M from the Moderna settlement, outlined plans to return up to ~$230M to shareholders, and highlighted ongoing international patent enforcement actions against Pfizer/BioNTech.
Sourcecatalyst · Owner execution record
At 12:19 PM ET, Alpha Intel recorded a purchase of 146.579823 ABUS shares at a $5.11 average fill, deploying $748.29. The position is explicitly classified as a Human Early-Entry Override.
SourceNo specific journal notes or briefs mentioning ABUS.
